Scribe Therapeutics is pioneering the development of CRISPR-based genetic medicines aimed at transforming healthcare, particularly in the realm of cardiometabolic diseases. The company has engineered two primary technologies: the CRISPR X-Editor (XE) and the Epigenetic Long-Term X-Repressor (ELXR). The XE technology focuses on precise gene editing, demonstrating significant reductions in apolipoprotein C-III (APOC3) and triglyceride levels, achieving over 90% reduction in preclinical models. Meanwhile, the ELXR technology offers a novel approach to epigenetic silencing, effectively lowering low-density lipoprotein cholesterol (LDL-C) by up to 67% in non-human primates without altering the underlying DNA sequence. Both technologies are designed to be safe and effective for broad patient populations, with a focus on minimizing off-target effects.

Scribe's innovative approach, termed "CRISPR by Design," emphasizes the importance of engineered specificity and potency in genetic therapies. The company has reported promising preclinical data validating the safety and efficacy of its platforms, showcasing their potential to provide durable and effective treatments for chronic diseases. By leveraging advanced molecular engineering techniques, Scribe aims to make genetic medicines accessible and beneficial for a wide range of patients, moving towards a future where genetic predispositions do not dictate health outcomes.

United States

Scribe is building and applying a suite of CRISPR technologies designed for therapeutic use into a single continually evolving and expanding genetic modification platform. Specifically, the company is working on NK cell therapies.

Scribe Therapeutics

Company Details